GEN Exclusives

More »

GEN News Highlights

More »
Apr 7, 2008

Ceragenix Awarded $1.5M from Dr. Reddy’s for Progress in Commercializing EpiCeram

  • Ceragenix Pharmaceuticals  received a $1.5 million milestone payment from Dr. Reddy’s Laboratories pursuant to the firms’ agreement to jointly commercialize EpiCeram® in the U.S.

    EpiCeram® is a topical nonsteroidal skin care cream that is scheduled to be launched later this year.

    As per the agreement, Ceragenix may earn nonsales based milestone payments of up to $3.5 million upon the accomplishment of three specified events inclusive of certain product launch specific considerations. The payment received from DRL represents the accomplishment of one such event and is refundable in the event that Ceragenix cannot provide launch quantities of a properly validated and shelf-stable product. The company feels confident that it can meet those requirements.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?